



Listing/Compliance Department,
BSE LTD, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai, 400 001

11.11.2020

BSE SCRIP CODE: 506405

Ref: Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

Subject: Investor Presentation on financial performance of Q2 Financial Year 2020-21.

Dear Sir/Ma'am,

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we are enclosing a copy of the Investor Presentation on Q2 for the Financial Year 2020-21 to be made to investors and analysts.

Please take the above on record.

Thanking You
Yours Faithfully

For **THE DHARAMSI MORARJI CHEMICAL COMPANY LIMITED**

D.T.Gokhale
Sr. Executive Vice President and
Company secretary

CIN NUMBER: L24110MH1919PLC000564

Earnings Presentation

Q2FY21 EARNINGS PRESENTATION
(November 2020)

BSE – DHARAMSI | 506405

Bloomberg – DMCC:IN

The Dharamsi Morarji Chemical Co. Limited

*100 + years of expertise in Sulphur
Chemistry*



THE DHARAMSI MORARJI CHEMICAL CO. LTD.



TOGETHER FOR
SUSTAINABILITY



Responsible Care®
OUR COMMITMENT TO SUSTAINABILITY

DMCC

Safe Harbour

This investor presentation has been prepared by Dharamsi Morarji Chemicals Company Limited (“DMCC”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements”, including those relating to the general business plans and strategy of DMCC, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, etc., or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to risks with respect to its hair care, its healthcare business and its skin care business. DMCC may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

QUARTERLY UPDATES

MANAGEMENT COMMENTARY

UPDATES ON CAPEX

FINANCIAL STATEMENT SUMMARY

CONTACT US

EARNINGS CALL DETAILS

Inside the
document

To view our corporate film
Visit: <https://bit.ly/3ePHS7S> or
Scan the QR code.



Financial Statement Summary

CONSOLIDATED P&L STATEMENT

Figures in INR Crores

PARTICULARS	Q2 FY21	Q1 FY21	Q2 FY20
Revenue from Operations	49.77	39.16	44.68
Total Income	55.88	39.53	44.89
Total Operating Expense	40.45	31.42	37.23
EBITDA *	15.43	8.11	7.66
EBITDA Margins %	31.0%	20.72%	17.15%
Interest Cost	0.73	0.42	0.60
Depreciation and Amortisation	1.73	1.64	1.56
Profit Before Taxes	12.97	6.05	5.50
Profit After Taxes	11.68	5.43	4.33

11.41% ▲

Q2FY21 Revenue from Operations at INR 49.77 crores as compared to INR 44.68 crores in Q2FY20

101.39% ▲

Q2FY21 EBITDA at INR 15.43 crores as compared to INR 7.66 crores in Q2FY20.

*This includes a profit of 4.94 crores on account of assignment/transfer of closed Khemli unit.

169.69% ▲

Q2FY21 Profit After Tax at INR 11.68 crores as compared to INR 4.33 crores in Q2FY20

CLICK HERE to view the financial results- <https://www.bseindia.com/xml-data/corpfiling/AttachLive/0eeba971-ef81-43d1-b705-9ad83f490fbb.pdf>

Financial Statement Summary

CONSOLIDATED BALANCE SHEET

Figures in INR Crores			
PARTICULARS	H1FY21	FY20	H1FY20
Shareholders Fund	160.39	144.88	126.71
Non Current Liabilities	17.65	20.22	16.38
Current Liabilities	44.01	46.78	52.81
Total	222.05	211.88	187.87
Non Current Assets	122.83	112.48	101.73
Current Assets	99.21	99.40	86.13
Total	222.05	211.88	187.87

CLICK HERE to view the financial results- <https://www.bseindia.com/xml-data/corpfiling/AttachLive/0eeba971-ef81-43d1-b705-9ad83f490fbb.pdf>

Financial Statement Summary

CONSOLIDATED CASH FLOW STATEMENT

Figures in INR Crores

PARTICULARS	H1FY21	FY20	H1FY20
Cash Flow From Operating Activities	14.57	26.99	13.14
Cash Flow from Investing Activities	(13.43)	(16.84)	(6.90)
Cash Flow from Financing Activities	(5.44)	(5.65)	(6.06)
Net increase/ decrease in cash and cash equivalents	(4.30)	4.49	0.18
Cash and Cash equivalents at beginning of year	8.31	3.81	3.81
Cash and Cash equivalents at end of year	4.02	8.31	3.99

CLICK HERE to view the financial results- <https://www.bseindia.com/xml-data/corpfiling/AttachLive/0eeba971-ef81-43d1-b705-9ad83f490fbb.pdf>

Management Remarks

FINANCIAL PERFORMANCE:

The revenues of the company in Q2FY21 increased by 11.41% to 49.77 cr. as compared to 44.68 cr. in Q2FY20. With opening up of the economy and the end user industries, the company witnessed operations returning back to pre-Covid levels.

The company recorded strong EBITDA margins of 31% in this quarter on the back of strong performance in specialty chemicals and better operating efficiencies at Dahej unit. Adjusting for the one-time profits from assignment /transfer of closed Khemli unit., the company managed to record an EBITDA of 10.49 cr. (21%) in Q2FY21 as compared to 7.66 cr. (17.15%) in Q2FY20

The Net-Profitability of the company in Q2FY21 increased by 169.69% to 11.68 cr. as compared to 4.34 cr. in Q2FY20.

PARTICULARS	Q2FY21	Q1FY21
Sales of Specialty chemicals including exports	~67%	~73%
Sales of Bulk Chemicals	~ 29%	~ 26%
Other Operating income	~4%	~1%

SEGMENT PERFORMANCE:

- The company witnessed strong recovery in specialty chemicals segment with reopening of domestic industries. The demand from export markets continued to remain strong during the quarter.
- The commodity segment of the boron business continued to face a challenging environment with availability of raw materials being a roadblock. However the company witnessed traction on the specialty part of the boron business.
- This was a normal quarter for the bulk chemicals segment and the company expects this performance to continue going forward.

FUTURE OUTLOOK:

- The company is witnessing a recovery in volumes in both bulk as well as specialty chemicals in the domestic markets as all industries are now fully operational. The management expects this momentum to continue going forward.
- The export market has done relatively well since the outbreak of the pandemic. Exports contributed ~ 34% of the total sales in Q2FY21 as compared to ~33% in Q1FY21. The industries in the export market have been fully operational, however the response to the 2nd wave of the pandemic in the European countries needs to be seen. The company remain cautiously optimistic in the exports business.
- The performance in Q3FY21 is expected to remain subdued on the back of planned maintenance.

Update on Capex

Bulk chemicals at Dahej	Specialty chemicals at Dahej	Debottlenecking at Roha	Multipurpose plants at Dahej	Intermediates
The company will be investing 50 cr. in adding incremental capacity in bulk chemicals segment.	The company will invest 20 cr. in a dedicated plant at Dahej facility.	The company will invest ~ 10 cr. on this project.	The company will further invest Rs. 10 cr. in 2 multipurpose plants at the Dahej facility.	The company has plans to invest Rs. 20 cr. for expansion to manufacture intermediates for pharmaceutical and agrochemical industry.
The company has been facing certain challenges in terms of delays from vendors, however the company is on track to complete the project by June 2021	The company will use this facility for contract manufacturing. The products to be manufactured and other details remain confidential as the company has signed an NDA.	Due to certain challenges faced, there is a delay in execution of this project. This is now expected to complete by March 2021	Due to certain challenges faced, there is a delay in execution of this project. This is now expected to complete by March 2021	This project is expected to complete by December 2021
	The plant is expected to begin commercial production in the 2nd half of 2021			The company had earlier decided to invest this amount in Sulfones. However with a downturn in international markets for the product category, that plan has been put on hold.

Financial Statement Summary

CONSOLIDATED P&L STATEMENT

Figures in INR Crores

PARTICULARS	FY17	FY18	FY19	FY20
Revenue from operations	189.50	180.76	227.57	187.66
Total income	190.03	181.65	228.57	193.89
Total operating expense	160.34	158.75	175.07	166.08
EBITDA	30.21	23.78	54.5	34.04
EBITDA margins %	15.94%	13.16%	23.95%	18.14%
Interest cost	5.02	3.96	2.77	2.03
Depreciation and amortisation	3.72	4.19	4.51	6.16
Profit Before Taxes	21.47	15.63	47.22	25.85
Profit After Taxes	17.04	12.29	46.14	31.46

Financial Statement Summary

CONSOLIDATED BALANCE SHEET

Figures in INR Crores

PARTICULARS	FY17	FY18	FY19	FY20
Shareholders Fund	59.83	72.77	115.78	144.88
Non Current Liabilities	18.40	23.85	19.53	20.22
Current Liabilities	70.80	57.79	52.96	46.77
Total	149.04	154.42	188.27	211.88
Non Current Assets	89.08	92.17	101.63	112.47
Current Assets	59.96	62.25	86.64	99.40
Total	149.04	154.42	188.27	211.88

Financial Statement Summary

CONSOLIDATED CASH FLOW STATEMENT

Figures in INR Crores

PARTICULARS	FY17	FY18	FY19	FY20
Cash Flow From Operating Activities	28.99	18.36	20.85	26.99
Cash Flow from Investing Activities	(8.31)	(9.17)	(12.69)	(16.84)
Cash Flow from Financing Activites	(18.71)	(9.05)	(8.13)	(5.65)
Net increase/ decrease in cash and cash equivalents	1.96	0.13	0.03	4.49
Cash and Cash equivalents at beginning of year	1.68	3.65	3.78	3.81
Cash and Cash equivalents at end of year	3.65	3.78	3.81	8.31

Get in Touch

MR. DILIP T GOKHALE

*Sr. Executive Vice President &
Company Secretary*

The Dharamsi Morarji Chemical
Co. Limited

dgokhle@dmcc.com



MR. ABHISHEK MEHRA

Investor Relations Advsiior

The Investment Lab

abhishek@theinvestmentlab.in





The Dharamsi Morarji Chemical Co. Ltd.



The Investment Lab

Q2FY21 RESULT DISCUSSION

We cordially invite you to a conference call with the management of **The Dharamsi Morarji Chemical Company Limited** to discuss the Q2FY21 Result of the company.

Management Participants

Mr. Bimal Goculdas (Managing Director and CEO)
Mr. Dilip Gokhale (Sr. Executive Vice President & Company Secretary)
Mr. Chirag Jaswant Shah (Chief Financial Officer)

Thursday, 12th November, 2020 at 4 PM (IST)

Conference Access Numbers:	
Universal DialIn	+91 22 6280 1341 +91 22 7115 8242
Local DialIn Available all over India	+91-7045671221

Express Join with DiamondPass™ No Wait Time

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=3233710&linkSecurityString=980d10504>

For Further Information, Contact :

Mr. Dilip Gokhale
(dgokhle@dmcc.com)

Mr. Abhishek Mehra
(abhishek@theinvestmentlab.in)